Please login to the form below

Not currently logged in
Email:
Password:

Pfizer strengthens board of directors

Ronald Blaylock brings financial and business leadership expertise

Pfizer Ronald BlaylockPfizer has bolstered its board of directors with the appointment of Ronald Blaylock, who joins with immediate effect.

Blaylock currently serves as managing partner of private equity firm GenNx360 Capital Partners, which he founded in 2006.

Prior to this, he founded investment banking firm Blaylock & Company in 1993, subsequently serving as chairman and chief executive officer.

He brings further senior management experience from Paine Webber and CitiGroup, and currently serves on the boards of CarMax, Radio One, WR Berkley and Syncreon.

Ian Read, Pfizer's chairman and chief executive officer, said: “We are pleased to welcome Ron Blaylock to Pfizer's board of directors.

“He brings business, financial and leadership expertise, which will be an asset to Pfizer's diverse board and to our company. The addition of Ron to our board helps to ensure that Pfizer continues to benefit from a breadth and variety of experience.”

28th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics